Remove Competition Remove FDA Remove Government Remove Prescription
article thumbnail

The debate on DTC marketing is going to heat up again

World of DTC Marketing

SUMMARY: DTC marketing is not the reason why prescription drugs cost so much. The FDA needs to study what people do when they see a DTC ad. Here are some myths around DTC marketing: 1ne: DTC ads result in patients asking for prescriptions they don’t need. DTC ads raise awareness around health conditions.

Marketing 285
article thumbnail

Your 2024 Legal Vision Board: Trends and Opportunities for Digital Health Innovators

Nixon Gwilt Law

Companies will also need to understand whether the FDA will consider their model to be software as a medical device (SaMD) that is subject to the FD&C Act. Rebecca says, “ New and existing companies will offer GLP-1 prescriptions for weight loss. The field is already saturated, so we will see companies exit as leaders emerge.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Selling Effectively In Medical Sales With John Crowder

Evolve Your Success

A lot of organizations that may have a sales model don’t probably follow the prescription that we deliver or the method that we deliver to them, which is why they contract us. You have to be able to talk about your product, especially in our field because it’s so governed by the FDA. That is true.

article thumbnail

FDA AdCom votes unanimously in favour of OTC oral contraceptive

Pharmaceutical Technology

A US Food and Drug Administration (FDA) Advisory Committee (AdCom) has voted unanimously in favour of giving HRA Pharma’s Opill (norgestrel) over-the-counter (OTC) availability. The FDA has no obligations to follow the recommendation of AdComs, though the vote will likely be weighed in the agency’s final decision.

FDA 52
article thumbnail

Exforge antitrust settlement caps Novartis’ year of legal disputes

Pharmaceutical Technology

The alleged actions violated the Hatch-Waxman Act, formally known as the “Drug Price Competition and Patent Term Restoration Act of 1984,” which allows generic manufacturers to market their generic versions of previously approved generic medications. These actions allegedly led to the extension of Novartis’ patents. Novartis vs Greece.

article thumbnail

OTC Narcan will cost ‘less than $50’, company says

Pharmaceutical Technology

Public interest groups including government agencies, harm reduction groups, and emergency responders pay less than $50 out of pocket for one carton of the spray, according to Emergent. On March 29, 2023, the US Food and Drug Administration (FDA) granted approval that made Narcan the opioid treatment drug to be sold without a prescription.

article thumbnail

Uri Goren

Cadensee

So, you see on one side, there's a special body of the FDA trying to listen to patients to find new targets for health and for pharmaceutical technology. But in terms of Israel as a competitive advantage, I think data is much more than just good technology. When do you think it is the most important? It's a different part of it.